Ra Pharmaceuticals, Inc.

Yili Sun

Douglas A Treco

Alonso Ricardo

Zhong Ma

Kristopher Josephson

Ping Ye

Kathleen Seyb

Nathan Ezekiel Nims

Guo-Qing Tang

Nicolas Cedric Boyer

Sylvia Tobe

Joseph R Stringer

Derek M LaPlaca

Douangsone D Vadysirisack

Kelli Jette

Derek M Laplaca

Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.

Cyclic polypeptides for PCSK9 inhibition

The present invention provides Ras modulators including inhibitors and/or antagonists of Ras, Ras binding, and Ras-dependent cell signaling activity. Also provided are methods of utilizing the Ras modulators as therapeutics.

Ras binding peptides and methods of use

Growing community of inventors

Cambridge, MA, United States of America

Yili Sun